원문정보
초록
영어
Hepatitis B virus (HBV) is one of the main pathogens responsible for hepatitis and hepatocellular carcinoma. Human plasma-derived Hepatitis B immune globulin (HBIG) is being used for prophylactic and liver transplantation currently. However, it may be necessary to replace a HBIG with a recombinant one because of limited availability of human plasma with high anti-HBs antibody titer and possible contamination of human pathogens.
To meet these requirements, a Chinese hamster ovary (CHO) cell line, HB-C7A, was established which produces a fully human IgG1 that binds HBV. The HB-C7A recognizes the conformational “a” determinant of HBsAg and binds HBV particle more efficiently than the Hepabig (a plasma-derived HBIG from Green Cross Corp., Yongin, Korea). The virus neutralizing efficacy of this antibody was proved using HBV-naïve chimpanzees. The HB-C7A exhibits ∼3500 units/mg of antibody and its affinity (Ka) is estimated ∼7 fold higher than that of Hepabig. The HB-C7A binds to HBVinfected human liver tissue but does not bind to normal human tissues. Currently it is in clinical phase I. In addition the possibility of chronic hepatitis B treatment by this
antibody was investigated. This HB-C7A has several advantages compared to the Hepabig such as activity, safety and availability.